



BIORETAIN[®]

Not All Tissue Processing Is Created Equal

A new retrospective study shows BioRetain processed Amnion/Chorion tissue outperforms leading laminated (L-AC) competitor.‡

Study focused on placental membrane wound covering for diabetic foot ulcers (DFUs).



BioRetain[®]-AC

Fewer applications 

Faster outcomes 

L-AC

More applications 

Smaller starting wound size 

THE BIORETAIN[®] PROCESSING DIFFERENCE

With fewer applications than L-AC, BioRetain helps achieve results faster. That means:

- Less hassle and more comfort for patients by not requiring additional treatment days
- Streamlined care for clinicians
- Smarter use of time + resources for everyone

Our patented BioRetain process protects the natural integrity of the Vendaje AC[®] placental tissue, preserving what matters most.



1
Gentle
**bioburden
reduction**



2
Manual blood
reduction



3
Cold isotonic
cleansing



4
Gentle, gradual
dehydration



5
Precise
cutting die
placement




6
Low-dose
terminal
sterilization

**BioRetain Retains The
Key Growth Factor
Hyaluronic Acid**

	Average $\mu\text{g}/\text{cm}^2$	SEM
Comp. X	3.25	0.71
Comp. Z	1.68	0.12
Vendaje AC	48.36	12.83

**Compared to top competitors,
BioRetain-processed V-AC
demonstrates nearly 10x more
HA than the nearest competitive
product tested.***

Hyaluronic Acid



FOR MORE INFORMATION

on the products manufactured using the BioRetain method, please visit our website.



Venture Medical, LLC | VentureMedical.com | 1-800-881-1809 | Missoula, MT

*Data on file.

† Frykberg, R. G., & Tunyisw, Z. (2024). Assessing placental membrane treatment efficiency in diabetic foot ulcers: Processing for retention versus lamination. Health Science Reports, 7(6), e2196.

